In 2016, Domain Therapeutics and Medicxi, a Swiss venture fund dedicated to financing asset-centric companies, created Mavalon Therapeutics. The company focuses on the development of first-in-class orally active positive allosteric modulator of the metabotropic glutamate receptor type 3 (mGluR3 PAM) to stop the progression of Parkinson’s disease. Medicxi committed up to €9m in Mavalon (see press release).

Program description

mGluR3 PAM

  • Discovery
  • Candidate
  • Preclinical
  • Clinical

mGlu3 receptor enhancers have been shown to relieve parkinsonian symptoms and to protect against nigrostriatal degeneration. The mechanisms behind are the inhibition of glutamate and the production of neurotrophic factors in the brain. These factors are important for the development and maintenance of neurons that produce dopamine, a key neurotransmitter lost in Parkinson’s disease.

We discovered a novel chemical family of mGluR3 PAMs with the support of the Michael J. Fox Foundation.

The mGluR3 PAM program was assigned to Mavalon and is currently at the lead optimization stage.

Other Programs

First-in-class CXCR4 agonist to control auto-immune diseases


New GPCRs target identification and validation